Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $2.2 million.

  • Insight Molecular Diagnostics' Accumulated Expenses rose 1689.4% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 1689.4%. This contributed to the annual value of $1.9 million for FY2024, which is 1758.64% up from last year.
  • According to the latest figures from Q3 2025, Insight Molecular Diagnostics' Accumulated Expenses is $2.2 million, which was up 1689.4% from $1.5 million recorded in Q2 2025.
  • Insight Molecular Diagnostics' 5-year Accumulated Expenses high stood at $4.1 million for Q3 2022, and its period low was $1.3 million during Q2 2023.
  • Over the past 5 years, Insight Molecular Diagnostics' median Accumulated Expenses value was $2.2 million (recorded in 2025), while the average stood at $2.3 million.
  • In the last 5 years, Insight Molecular Diagnostics' Accumulated Expenses surged by 13828.96% in 2021 and then plummeted by 5765.92% in 2023.
  • Quarter analysis of 5 years shows Insight Molecular Diagnostics' Accumulated Expenses stood at $2.8 million in 2021, then decreased by 28.48% to $2.0 million in 2022, then fell by 18.45% to $1.6 million in 2023, then rose by 17.59% to $1.9 million in 2024, then rose by 14.9% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q3 2025, $1.5 million for Q2 2025, and $2.5 million during Q1 2025.